Of note, over the last years, an array of unimolecular GLP1-based poly-agonists, with different mechanisms of action, have been developed and experimentally validated for the treatment of metabolic syndrome, holding superior efficacy relative to conventional GLP1-RA 33,34,35
Keep Meal Timing Consistent GLP-1 medications reduce appetite
In mice with DIO, chronic treatment (every 3 days for 22 days) with 10 nmol/kg tirzepatide resulted in weight loss that was greater than that observed with similar treatment with 30 nmol/kg semaglutide
Several basic molecular and cellular mechanisms are shared among brain diseases, such as neuroinflammation, oxidative stress, excitotoxicity, neurodegeneration, disorders of neurogenesis, dysfunction of neurotrophic factor systems, which are most prominent in specific brain structures associated with different brain diseases [104, 105]